Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep ( (IMMP) ) has provided an announcement.
On April 15, 2026, Immutep announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to its lead candidate eftilagimod alfa for treating soft tissue sarcoma, a rare cancer with high unmet need. The status, which can provide regulatory support, tax incentives, fee waivers and potential market exclusivity, underscores the promise of efti in a niche oncology indication.
The designation is supported by Phase II EFTISARC-NEO trial data in 38 patients, where efti combined with radiotherapy and pembrolizumab met its primary endpoint with median tumour hyalinization/fibrosis of 51.5%, far above historical benchmarks. While Immutep is still reassessing its broader efti strategy after discontinuing the Phase III TACTI-004 trial, management says the new status could enable a more direct path into a late-stage neoadjuvant study in soft tissue sarcoma, potentially reshaping the program’s future and strengthening the company’s rare oncology positioning.
The most recent analyst rating on (IMMP) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Underperform.
The score is primarily held down by weak financial performance, including persistent losses and negative operating/free cash flow. Technicals add further pressure due to a broader downtrend and negative MACD, though near-oversold RSI/Stoch modestly offsets this. Valuation is also constrained by a negative P/E and no dividend yield data.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep Limited is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The company is a pioneer in LAG-3 biology, building a diversified product portfolio that aims to either stimulate or suppress the immune response, with a focus on delivering new treatment options to patients and creating value for shareholders.
Average Trading Volume: 14,244,401
Technical Sentiment Signal: Sell
Current Market Cap: $76.16M
See more data about IMMP stock on TipRanks’ Stock Analysis page.